This is only the beginning for the S670. This stent is not fully available as it is being slowly rolled out. It is only in a very small number of accounts. To get to this level of market share with limited release would tell me they are on a roll. I would have to think to get to a market share of 16% that the share in the accounts where the stent is released would be at or over 50%.
The only mistake this report made was not stating that MDT will take market share from GDT. As we move forward the company to be hit the hardest is BSX. But GDT will take a hit also. Just my conjecture but buy the stock before everyone else figures this out.
Best of luck,
Mike
MD DataDirect Reports Medtronic Gains Coronary Stent Market Share with New S670 Stent
Web-Based Data Service Tracks More Than 6,000 Medical Products
MENLO PARK, Calif., Jan. 14 /PRNewswire/ -- MD DataDirect, a leading Internet provider of comprehensive real-time medical product usage information, today announced that the new S670 stent manufactured by Medtronic (NYSE: MDT) emerged as the second most used stent at 17 high-volume U.S. cardiovascular treatment centers during the fourth quarter of 1999. Since its introduction mid-quarter, the S670 has captured 16 percent of the usage share at these reporting hospitals.
Medtronic's gain in market share negatively impacted other medical device manufacturers including Boston Scientific. Despite the increasing appeal of the S670, Guidant maintained its apparent dominant market position with the Multi-Link Duet stent, which represented 53 percent of the stent market among these leading cardiovascular treatment centers. The new Guidant Tristar stent was introduced too late to materially impact this market segment.
While not intended to be representative of the entire market, the product usage data that is reported to MD DataDirect is considered a bellwether indicator of trends in the cardiology marketplace because of the quality of the reporting sources. To-date, over 400 high-volume cardiology specialists who are considered to be thought-leaders in their field, have signed on as exclusive sources of data.
"The clinical usage patterns obtained and assembled by MD DataDirect on over 6,000 cardiovascular products provide important insight into developing trends in the marketplace," commented Doug Murphy-Chutorian, M.D., Chairman of MD DataDirect. "Such market intelligence is not readily available from retrospective product purchase data typically reported. We are very excited about the quality and utility of our proprietary market data and are confident that this market intelligence will be valuable to practicing physicians, providers, manufactures, investors and other interested parties."
MD DataDirect, located in Menlo Park, California, is a web-based service provider of real-time medical product usage data and e-commerce services. The company gathers, compiles and reports comprehensive medical device usage patterns from top U.S. medical centers. MD DataDirect also provides qualitative surveys and interviews with a broad range of clinical users. Subscribers also have one-on-one opportunities to query top physicians regarding their product usage opinions through MD DirectLine, a feature on the MD DataDirect Web site. Additional information is available at mddatadirect.com.
MD DataDirect receives no advertisements from any of the manufacturers or suppliers of the products or services identified in this press release. Readers are advised that this press release is issued solely for information purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. The data and analysis included herein are based on sources believed to be reliable and in good faith but no representation or warranty, expressed or implied, is made as to their accuracy, completeness or correctness. Any opinions expressed in any report are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere. Neither MD DataDirect nor any of its officers, directors, partners or employees/consultants accept any liability whatsoever for any direct or consequential loss arising from any use of this press release or its contents. |
